Evidence map›Paper›PMID 35177010›Full record

ReviewBMC psychiatry2022

A review of economic evaluations of health care for people at risk of psychosis and for first-episode psychosis.

Gemma E Shields, Deborah Buck, Filippo Varese, Alison R Yung, Andrew Thompson, Nusrat Husain, Matthew R Broome, Rachel Upthegrove, Rory Byrne, Linda M Davies

Abstract readReview
In one paragraph

Review in BMC psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gemma E ShieldsManchester Centre for Health Economics, Division of Population Health, School of Health Sciences, University of Manchester, Manchester, UK. gemma.shields@manchester.ac.uk.
Deborah BuckManchester Centre for Health Economics, Division of Population Health, School of Health Sciences, University of Manchester, Manchester, UK.
Filippo VareseDivision of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
Alison R YungDivision of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
Andrew ThompsonOrygen, The Centre of Excellence in Youth Mental Health, University of Melbourne, Melbourne, Australia.
Nusrat HusainDivision of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, UK.
Matthew R BroomeInstitute for Mental Health, University of Birmingham, Birmingham, UK.
Rachel UpthegroveInstitute for Mental Health, University of Birmingham, Birmingham, UK.
Rory ByrneGreater Manchester Mental Health NHS Foundation Trust, Manchester, UK.
Linda M DaviesManchester Centre for Health Economics, Division of Population Health, School of Health Sciences, University of Manchester, Manchester, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPreventing psychotic disorders and effective treatment in first-episode psychosis are key priorities for the National Institute for Health and Care Excellence. This review assessed the evidence base for the cost-effectiveness of health and social care interventions for people at risk of psychosis and for first-episode psychosis.

methodsElectronic searches were conducted using the PsycINFO, MEDLINE and Embase databases to identify relevant published full economic evaluations published before August 2020. Full-text English-language studies reporting a full economic evaluation of a health or social care intervention aiming to reduce or prevent symptoms in people at risk of psychosis or experiencing first-episode psychosis were included. Screening, data extraction, and critical appraisal were performed using pre-specified criteria and forms based on the NHS Economic Evaluation Database (EED) handbook and Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist for economic evaluations. The protocol was registered on the PROSPERO database (CRD42018108226). Results were summarised qualitatively.

resultsSearching identified 1,628 citations (1,326 following the removal of duplications). After two stages of screening 14 studies met the inclusion criteria and were included in the review. Interventions were varied and included multidisciplinary care, antipsychotic medication, psychological therapy, and assertive outreach. Evidence was limited in the at-risk group with only four identified studies, though all interventions were found to be cost-effective with a high probability (> 80%). A more substantial evidence base was identified for first-episode psychosis (11 studies), with a focus on early intervention (7/11 studies) which again had positive conclusions though with greater uncertainty.

conclusionsStudy findings generally concluded interventions were cost-effective. The evidence for the population who are at-risk of psychosis was limited, and though there were more studies for the population with first-episode psychosis, limitations of the evidence base (including generalisability and heterogeneity across the methods used) affect the certainty of conclusions.

Indexed as

Antipsychotic AgentsPsychotic DisordersCost-Benefit AnalysisDelivery of Health CareHumansTreatment OutcomeAntipsychotic AgentsCost-effectivenessCost-utilityEconomic evaluationPsychosisSystematic review

Identifiers

PMID35177010
PMCPMC8851734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.